Latest Breaking News On - Christelle huguet - Page 1 : vimarsana.com

FDA approves Ipsen s Iqirvo to address unmet need in primary biliary cholangitis

The FDA granted accelerated approval to Ipsen Pharma’s Iqirvo 80 mg, a first-in-class oral, once-daily peroxisome proliferator-activated receptor agonist for the treatment of primary biliary cholangitis, according to a company release. Originally given breakthrough therapy designation in 2019, Iqirvo (elafibranor, Ipsen/Genfit), is now indicated as second-line therapy in combination with

United kingdomUnited statesIpsen iqirvoKris kowdleyIpsen genfitRobert stottChristelle huguetIpsen pharma iqirvoEuropean medicines agencyRegulatory agencyLiver instituteIpsen pharmaLiver institute northwestUnited kingdom medicines

FDA Grants Accelerated Approval to Elafibranor (Iqirvo) for PBC

The accelerated approval is based on data from the phase 3 ELATIVE trial demonstrating a reduction in alkaline phosphatase with elafibranor.

United kingdomUnited statesKris kowdleyChristelle huguetIpsen iqirvoLiver instituteHealthcare products regulatory authorityDrug administrationEuropean medicines agencyAmerican associationLiver diseaseLiver institute northwestEuropean associationUnited kingdom medicinesHealthcare products regulatoryBreakthrough therapy designation

Newswire & Press Release / Ipsen s Iqirvo® Receives U S FDA Accelerated Approval as A First-in-class PPAR Treatment for Primary Biliary - Pharma / BioTech / Nutrition - IPSEN Group

Newswire & Press Release / Ipsen s Iqirvo® Receives U S FDA Accelerated Approval as A First-in-class PPAR Treatment for Primary Biliary - Pharma / BioTech / Nutrition - IPSEN Group
newswiretoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newswiretoday.com Daily Mail and Mail on Sunday newspapers.

United statesHong kongUnited kingdomFrance generalChristelle huguetIpsen iqirvoCarol robertsKris kowdleyLiver instituteEuropean medicines agencyAgency sourceIpsen pharmaceuticalsDrug administrationRegulatory agencyNewborn developmentIpsen pharmaceuticals inc

Newswire & Press Release / Ipsen s Iqirvo® Receives U S FDA Accelerated Approval as A First-in-class PPAR Treatment for Primary Biliary - Pharma / BioTech / Nutrition - IPSEN Group

Hong kongUnited statesFrance generalUnited kingdomChristelle huguetKris kowdleyCarol robertsIpsen iqirvoHead of researchIpsen pharmaceuticals incNewborn developmentRegulatory agencyLiver instituteAgency sourceIpsen pharmaceuticalsEuropean medicines agency

Ipsen s Iqirvo® receives U S FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis | Company Announcement

Ipsen s Iqirvo® receives U S FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis | Company Announcement
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.

United statesFrance generalUnited kingdomHong kongIpsen euronextClin gastroenterol hepatolCarol robertsChristelle huguetAnna gibbinsIpsen iqirvoRachel reiffKris kowdleyNicolas boglerAmy wolfLiver instituteIpsen pharmaceuticals inc